South Sudan recalls Duphaston and Navidoxine over quality and falsification concerns
South Sudan’s Drug and Food Control Authority (DFCA) has ordered the immediate recall of medicines sold as Duphaston and Navidoxine.
The directive, dated 1 September 2026, was signed by Dr Peter Aguek Kon Baak, Director General for Inspection and Surveillance. It instructs pharmaceutical wholesalers, retail pharmacies and healthcare facilities—particularly gynaecology departments—to withdraw the products from circulation and contact DFCA inspectors.
The notice cites medicine-quality, suspected falsification and patient-safety concerns. It states that inspectors identified concerns involving Duphaston during the previous week, although the recall applies to both Duphaston and Navidoxine.
Duphaston has previously been the subject of falsification alerts in other countries. Pakistan’s Drug Regulatory Authority has reported spurious batches, including one reportedly found to contain no active ingredient.
Drug Eye Africa previously reported concerns in Somalia involving products sold under the same brand names and allegedly linked to Pakistan-based trader Taqwa Pharmaceutical & Surgical. This does not establish a common source, but the overlap warrants coordinated investigation by authorities in South Sudan, Somalia and Pakistan.
Drug Eye Africa holds a signed and stamped copy of the DFCA recall directive.
